EDITAS MEDICINE, INC. Defined Contribution Plan, Cost
EDITAS MEDICINE, INC. (EDIT) reported Defined Contribution Plan, Cost of $1.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-09
- EDITAS MEDICINE, INC. defined contribution plan, cost for fiscal 2025 was $1.20M, a 29.41% decline from fiscal 2024.
- EDITAS MEDICINE, INC. defined contribution plan, cost for fiscal 2024 was $1.70M, a 41.67% increase from fiscal 2023.
- EDITAS MEDICINE, INC. defined contribution plan, cost for fiscal 2023 was $1.20M, a 14.29% decline from fiscal 2022.
- EDITAS MEDICINE, INC. defined contribution plan, cost for fiscal 2022 was $1.40M, a 16.67% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $1.20M 10-K · filed 2026-03-09 |
| 2024-12-31 | $1.70M 10-K · filed 2026-03-09 |
| 2023-12-31 | $1.20M 10-K · filed 2025-03-05 |
| 2022-12-31 | $1.40M 10-K · filed 2025-03-05 |
| 2021-12-31 | $1.20M 10-K · filed 2024-02-28 |
| 2020-12-31 | $1.10M 10-K · filed 2023-02-22 |
| 2019-12-31 | $800.00K 10-K · filed 2022-02-24 |
| 2018-12-31 | $700.00K 10-K · filed 2021-02-26 |
| 2017-12-31 | $500.00K 10-K · filed 2020-02-26 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-08 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |